Preclinical and clinical studies of MMP inhibitors in cancer

被引:179
作者
Drummond, AH [1 ]
Beckett, P [1 ]
Brown, PD [1 ]
Bone, EA [1 ]
Davidson, AH [1 ]
Galloway, WA [1 ]
Gearing, AJH [1 ]
Huxley, P [1 ]
Laber, D [1 ]
McCourt, M [1 ]
Whittaker, M [1 ]
Wood, LM [1 ]
Wright, A [1 ]
机构
[1] British Biotechnol Ltd, Oxford OX4 5LY, England
来源
INHIBITION OF MATRIX METALLOPROTEINASES: THERAPEUTIC APPLICATIONS | 1999年 / 878卷
关键词
D O I
10.1111/j.1749-6632.1999.tb07688.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The role of matrix metalloproteinases in tumor angiogenesis and growth is now well recognized for models of both human and animal cancer. Clinical studies currently under way with the prototype matrix metalloproteinase inhibitor, marimastat, will establish whether inhibitors of these enzymes are of benefit in the treatment of different types of human cancer. On chronic therapy in humans, marimastat induces a reversible tendinitis that can also be detected in certain animal species. This paper compares the ability of broad-spectrum and various types of selective matrix metalloproteinase inhibitors to induce tendinitis and to exhibit anticancer effects in an animal cancer model. Under conditions in which both systemic exposure and inhibitor potency are controlled, selective inhibitors are less pro-tendinitic, but are weaker anticancer agents than broad-spectrum agents such as marimastat. The clinical relevance of these findings is discussed.
引用
收藏
页码:228 / 235
页数:8
相关论文
共 24 条
[1]   Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor [J].
An, ZL ;
Wang, XE ;
Willmott, N ;
Chander, SK ;
Tickle, S ;
Docherty, AJP ;
Mountain, A ;
Millican, AT ;
Morphy, R ;
Porter, JR ;
Epemolu, RO ;
Kubota, T ;
Moossa, AR ;
Hoffman, RM .
CLINICAL & EXPERIMENTAL METASTASIS, 1997, 15 (02) :184-195
[2]   Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors [J].
Arribas, J ;
Coodly, L ;
Vollmer, P ;
Kishimoto, TK ;
RoseJohn, S ;
Massague, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (19) :11376-11382
[3]   Recent advances in matrix metalloproteinase inhibitor research [J].
Beckett, RP ;
Davidson, AH ;
Drummond, AH ;
Huxley, P ;
Whittaker, M .
DRUG DISCOVERY TODAY, 1996, 1 (01) :16-26
[4]   A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells [J].
Black, RA ;
Rauch, CT ;
Kozlosky, CJ ;
Peschon, JJ ;
Slack, JL ;
Wolfson, MF ;
Castner, BJ ;
Stocking, KL ;
Reddy, P ;
Srinivasan, S ;
Nelson, N ;
Boiani, N ;
Schooley, KA ;
Gerhart, M ;
Davis, R ;
Fitzner, JN ;
Johnson, RS ;
Paxton, RJ ;
March, CJ ;
Cerretti, DP .
NATURE, 1997, 385 (6618) :729-733
[5]   Relaxed specificity of matrix metalloproteinases (MMPS) and TIMP insensitivity of tumor necrosis factor-alpha (TNF-alpha) production suggest the major TNF-alpha converting enzyme is not an MMP [J].
Black, RA ;
Durie, FH ;
OttenEvans, C ;
Miller, R ;
Slack, JL ;
Lynch, DH ;
Castner, B ;
Mohler, KM ;
Gerhart, M ;
Johnson, RS ;
Itoh, Y ;
Okada, Y ;
Nagase, H .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 225 (02) :400-405
[6]   Matrix metalloproteinase inhibitors in the treatment of cancer [J].
Brown, PD .
MEDICAL ONCOLOGY, 1997, 14 (01) :1-10
[7]  
COLLIER IE, 1988, J BIOL CHEM, V263, P6579
[8]  
CRIMMIN MJ, 1993, Patent No. 5691382
[9]  
Drummond A. H., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P100
[10]  
DUNCAN ME, 1996, BIOCH SOC T, V24, P3295